Methods| This study comprised four 3-month periods. One period, during the first peak of the
pandemic in the New England area of the United States (from March 2 to June 2, 2020), 1 …

Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …

Importance Non-Hispanic Black individuals experience a higher burden of COVID-19 than
the general population; hence, there is an urgent need to characterize the unique clinical …

Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality and may
be more common in patients with cancer treated with immunotherapy (IO) due to immune …

Importance Androgen deprivation therapy (ADT) has been theorized to decrease the severity
of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in …

Background In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of nivolumab
and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, …

Patients with cancer, both active and previously treated, may be at higher risk of severe
outcomes from COVID-19 compared to the general population (Dai et al., 2020; Bakouny et al., …

Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune
checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 …

Background There are limited data evaluating the activity of cabozantinib (CABO) as
second line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno-…

… Andrew L. Schmidt … (Healthcare Communications Company with several brands such as
OnClive, PeerView and PER), Research to Practice, L‐path, Kidney Cancer Journal, Clinical Care …